Register
Forgot your password?

Once again about the new coronavirus infection COVID-19

Authors: Golukhova E.Z.

Company: Bakoulev National Medical Research Center for Cardiovascular Surgery, Moscow, Russian Federation

Type:  Editorial article


DOI: https://doi.org/10.24022/1997-3187-2021-15-2-141-145

For citation: Golukhova E.Z. Once again about the new coronavirus infection COVID-19. Creative Cardiology. 2021; 15 (2): 141–5 (in Russ.). DOI: 10.24022/1997-3187-2021-15-2-141-145

Received / Accepted:  28.06.2021

Keywords: complications extracorporeal membrane oxygenation multisystem inflammation syndrome neurological manifestation mortality

Download
Full text:  

 

Abstract

The COVID-19 pandemic continues to affect millions of people with increasing morbidity and mortality. Substantial variations exists in drug treatment of COVID-19. Extracorporeal membrane oxygenation (ECMO) facilitates survival of select critically ill patients with COVID-19 with about 25–45% survival rate; survivors tend to be younger and have a shorter duration from diagnosis to cannulation. The practioners found the severe complications including concomitant neurological manifestations (from headache, anosmia, ageusia to encephalopathy, stroke and others) and multisystem inflammation syndrome (MIS) predominantly in children few weeks after SARS-CoV-2 infection and characterized by persistent fever, vomiting, headache, Kawasaki – like rash and fatigue. Regarding MIS the authors did not find strong association between the complications rate and outcomes and regime of immunomodulation treatment. The neurological manifestations in pts with COVID-19 were associated with higher in-hospital mortality.

References

  1. Mallapaty S. Will the COVID-19 become the disease of the young? Nature. 2021; 595: 343–4. DOI: 10.1038/d41586-021-01862-7
  2. Jacobs J.P., Stammers A.H., St. Louis J.D., Hayanga A., Firstenberg M.S., Mongero L.B. et al. Multi-institutional analysis of 200 COVID-19 patients treated with ECMO: outcomes and trends. Ann. Thorac. Surg. 2021. DOI: 10.1016/j.athoracsur.2021.06.026
  3. Chou S.H., Bedhi E., Helbok R., Moro E., Sampson J., Altamirano V. et al. Global incidence of neurological manifestations among patients hospitalized with COVID-19 – a report for the GCSNeuroCOVID consortium and the energy consortium. JAMA. 2021; 4 (5); e2112131. DOI: 10.1001/jamanetworkopen.2021.12131
  4. Andrews M., Mukhtar T., Eze U., Simoneau C., Perez Y., Mostajo-Radji M.A. Tropism of SARSCoV-2 for developing human cortical astrocytes. 2021. DOI: 10.1101/2021.01.17.427024
  5. McArdle A.J., Vito O., Patel H., Seaby E.G., Shah P., Wilson C. et al. Treatment of multisystem inflammatory syndrome in children. N. Engl. J. Med. 2021; 385 (1): 11–22. DOI: 10.1056/nejmoa 2102968
  6. Al-Aly Z., Xie Y., Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. Nature. 2021; 594

About Authors

Elena Z. Golukhova, Dr. Med. Sci., Professor, Academician of RAS, Director; ORCID

Chief Editor

Elena Z. Golukhova, MD, PhD, DSc, Professor, Academician of Russian Academy of Sciences, Director of Bakoulev National Medical Research Center for Cardiovascular Surgery


Sort by